Kanamycin Sulfate for Injection

Kanamycin sulfate is an aminoglycoside antibiotic. This product has good antibacterial effects on most Enterobacteriaceae such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, Citrobacter, Providencia, Yersinia, etc.; Haemophilus influenzae, Brucella, Neisseria meningitidis, Neisseria gonorrhoeae, etc. are also mostly sensitive to this product. Kanamycin also has a certain effect on Staphylococcus (methicillin-sensitive strains) and Mycobacterium tuberculosis, but is ineffective against Pseudomonas aeruginosa. Other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, Enterococcus and anaerobic bacteria are mostly resistant to this product. In recent years, the number of resistant strains has increased significantly, because some bacteria produce aminoglycoside inactivating enzymes, which make them lose their antibacterial activity. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides. This product mainly binds to the bacterial ribosome 30S subunit and inhibits bacterial protein synthesis.

Kanamycin Sulfate

The product is suitable for serious infections caused by sensitive Enterobacteriaceae such as Escherichia coli, Klebsiella, Proteus, Enterobacter aerogenes, Shigella, etc., such as pneumonia, sepsis, abdominal infection, etc., and often needs to be used in combination with other antibacterial drugs.

1. The common dosage for adults is 0.5 g for intramuscular injection or intravenous drip, once every 12 hours; or 7.5 mg/kg per body weight, once every 12 hours. The daily dosage for adults should not exceed 1.5 g, and the course of treatment should not exceed 14 days. The dosage should be appropriately reduced for patients over 50 years old. 2. The common dosage for children is 15-25 mg/kg per day for intramuscular injection or intravenous drip, divided into 2 doses. 3. 0.25% solution of kanamycin sulfate can be used as a flushing solution. 0.1% solution can also be used for aerosol inhalation. 2.5% injection can be used for intraperitoneal administration. 4. Dosage for impaired renal function: When creatinine clearance is 50-90 mg/min, use 60%-90% of the normal dose, once every 12 hours (normal dose is 7.5 mg/kg each time, once every 12 hours); when creatinine clearance is 10-50 ml/min, use 30%-70% of the normal dose, once every 12-18 hours; when creatinine clearance is <10 mg/min, use 20%-30% of the normal dose, once every 24-48 hours.

Kanamycin sulfate is an aminoglycoside antibiotic. This product has good antibacterial effects on most Enterobacteriaceae such as Escherichia coli, Klebsiella, Enterobacter, Proteus, Shigella, Salmonella, Citrobacter, Providencia, Yersinia, etc.; Haemophilus influenzae, Brucella, Neisseria meningitidis, Neisseria gonorrhoeae, etc. are also mostly sensitive to this product. Kanamycin also has a certain effect on Staphylococcus (methicillin-sensitive strains) and Mycobacterium tuberculosis, but is ineffective against Pseudomonas aeruginosa. Other Gram-positive bacteria such as hemolytic streptococci, Streptococcus pneumoniae, Enterococcus and anaerobic bacteria are mostly resistant to this product. In recent years, the number of resistant strains has increased significantly, because some bacteria produce aminoglycoside inactivating enzymes, which make them lose their antibacterial activity. Kanamycin has complete cross-resistance with streptomycin and neomycin, and may have partial cross-resistance with other aminoglycosides. This product mainly binds to the bacterial ribosome 30S subunit and inhibits bacterial protein synthesis.

Patients with a history of allergy to this product or other aminoglycosides are contraindicated.

1. When used in combination with other aminoglycosides or when applied topically or systemically in sequence, it may increase ototoxicity, nephrotoxicity and neuromuscular blocking effects. 2. When used in combination with neuromuscular blockers, it may aggravate neuromuscular blocking effects, leading to muscle weakness, respiratory depression, etc. 3. When used in combination with capreomycin, cisplatin, ethacrynic acid, furosemide or vancomycin (or norvancomycin), or when applied topically or systemically in sequence, it may increase ototoxicity and nephrotoxicity. 4. When used topically or systemically with cephalothin or cefazolin, it may increase nephrotoxicity. 5. When used in combination with polymyxin injections, or when applied topically or systemically in sequence, it may increase nephrotoxicity and neuromuscular blocking effects. 6. Other nephrotoxic and ototoxic drugs should not be used in combination with this product or applied topically in sequence to avoid aggravating nephrotoxicity or ototoxicity. 7. When aminoglycosides and b-lactams (cephalosporins and penicillins) are mixed, they may lead to mutual inactivation. When this product is used in combination with the above antibiotics, it must be dripped in separate bottles. It is also not suitable to drip in the same bottle with other drugs.

Keep tightly closed in a dry place.

1.0g (1 million units)

Suzhou First Pharmacertical Co., Ltd.

• Founded in:

  2005-12-23

• Address:

  No. 1 Hualing Street, Suzhou Industrial Park

• Tax NO.:

  91320594783360722P

• Registered Funds:

  181.625 million yuan

• Email:

  Log in to view